Recently, birth control has been in the national news, first as a political issue and secondly as product recalls. This month, we have seen Pfizer and Glenmark Generics recall their oral contraceptives due to packaging issues.
According to the Centers for Disease Control and Prevention (CDC), ʺalmost half of all pregnancies are unintended in the U.S. In the United States, most women of reproductive age use birth control. Between the years 2006 through 2008, 99 percent of women who had ever had sexual intercourse used at least one method of birth control. ʺ
The CDC website revealed ʺthe most popular method of birth control was the oral contraceptive pill, used by 10.7 million women in the United States.ʺ
One oral contraceptive on the market is called Junel. This is the generic form of Loestrin. Loestrin is made by Teve Pharmaceuticals and Junel is produced by Barr Pharmaceuticals. Depending on where you live, Junel costs approximately $30 dollars per month.
Junel is a combined type of birth control pill which contains estrogen as well as progesterone. This type of pill is known as monophasic because it has a constant dose of both progesterone and estrogen over 21 days.
Junel is the type of oral contraceptive which prevents the egg from being released from the ovary.
Junel comes in four package types:
• Junel ®Fe 1.5/30 (28 Tablets)
• Junel ® 1.5/30 (21 Tablets)
• Junel ® Fe 1/20 (28 Tablets)
• Junel ® 1/20 (21 Tablets)
The Junel Fe packaging includes 7 iron tablets.
The Drugs.com website stated, ʺOral contraceptives should not be used in women who currently have the following conditions:ʺ
• Known or suspected pregnancy
• Hepatic adenomas or carcinomas
• Thrombophlebitis or thromboembolic disorders
• A past history of deep vein thrombophlebitis or thromboembolic disorders
• Cholestatic jaundice of pregnancy or jaundice with prior pill use
• Cerebral vascular or coronary artery disease
• Undiagnosed abnormal genital bleeding
• Known or suspected carcinoma of the breast
• Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia